首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   42907篇
  免费   4286篇
  国内免费   38篇
耳鼻咽喉   266篇
儿科学   1462篇
妇产科学   1228篇
基础医学   5823篇
口腔科学   808篇
临床医学   6119篇
内科学   7243篇
皮肤病学   639篇
神经病学   3868篇
特种医学   1588篇
外国民族医学   3篇
外科学   5067篇
综合类   864篇
一般理论   70篇
预防医学   5461篇
眼科学   995篇
药学   3105篇
中国医学   85篇
肿瘤学   2537篇
  2021年   776篇
  2020年   442篇
  2019年   729篇
  2018年   786篇
  2017年   656篇
  2016年   708篇
  2015年   739篇
  2014年   1030篇
  2013年   1537篇
  2012年   2262篇
  2011年   2293篇
  2010年   1315篇
  2009年   1168篇
  2008年   2057篇
  2007年   2179篇
  2006年   2114篇
  2005年   2045篇
  2004年   2062篇
  2003年   1875篇
  2002年   1784篇
  2001年   1274篇
  2000年   1292篇
  1999年   1115篇
  1998年   528篇
  1997年   452篇
  1996年   426篇
  1995年   360篇
  1994年   392篇
  1993年   371篇
  1992年   848篇
  1991年   822篇
  1990年   794篇
  1989年   707篇
  1988年   708篇
  1987年   675篇
  1986年   613篇
  1985年   686篇
  1984年   555篇
  1983年   451篇
  1982年   296篇
  1981年   296篇
  1980年   276篇
  1979年   476篇
  1978年   364篇
  1977年   269篇
  1976年   284篇
  1975年   265篇
  1974年   297篇
  1973年   269篇
  1972年   272篇
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
Erosive pustular dermatosis of the scalp (EPDS) is an uncommon chronic inflammatory response to scalp trauma that usually resolves with cicatricial alopecia. It most commonly affects elderly patients with a history of actinic damage. Herein, we describe a 16‐year‐old girl with acrofacial dysostosis type 1 presenting after surgery with crusting purulent scalp lesions, whose clinical presentation and histopathologic findings were consistent with EPDS. A review of the literature on EPDS in children is also detailed.  相似文献   
3.
4.
5.
6.
7.
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma  相似文献   
8.
Contrast‐enhanced spectral mammography (CESM) has a number of uses including the work‐up of inconclusive findings on mammography, assessment of breast symptoms, cancer staging, evaluation of response to neoadjuvant chemotherapy and recently as an alternative to magnetic resonance imaging (MRI) in high‐risk screening. CESM can be swiftly incorporated into the workflow of busy breast clinics. We share our experiences with CESM at a large breast assessment centre in Western Australia.  相似文献   
9.
10.

Introduction/Hypothesis

Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.

Methods

An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.

Results

A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.

Conclusions/Recommendations

Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号